Rallybio Corporation (RLYB) Stock Forecast
RLYB analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $8.00 average of analyst targets
- Upside to target
- −50.9% from the latest close
- Next earnings
- November 5, 2026
- 52-week range
- $4.33 – $17.22
RLYB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RLYB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.44 | −$1.44 | −$1.44 | $2.88 | −150.0% | 1 |
| Current fiscal year (2026) | −$5.52 | −$5.52 | −$5.52 | −$1.59 | −247.2% | 1 |
| Next fiscal year (2027) | −$3.60 | −$3.60 | −$3.60 | −$4.60 | +21.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RLYB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
RLYB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RLYB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.44 | −$1.44 | −$1.44 | −$1.44 | −$1.44 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$9.17 | −$9.17 | −$5.40 | −$5.40 | −$5.52 | −39.8% | 0 up · 0 down |
| Next fiscal year (2027) | −$3.60 | −$3.60 | −$3.60 | −$3.60 | −$3.60 | 0.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RLYB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RLYB beat in 7 of 12.
What analysts expect from RLYB
The average price target is $8.00, 50.9% below the latest close of $16.28. Analysts expect earnings of −$5.52 per share for 2026, −247.2% from a year earlier. For 2027 the average estimate is −$3.60 per share. Rallybio beat the EPS estimate in 7 of the last 12 quarters.
Related: RLYB income statement, RLYB key metrics, RLYB chart. See the RLYB stock overview for the latest quote and news.
RLYB forecast FAQ
What is Rallybio's price target?
The average analyst price target for Rallybio is $8.00, 50.9% below the latest close of $16.28.
What is Rallybio's EPS forecast?
Analysts forecast −$5.52 per share for 2026 (range −$5.52 to −$5.52); for 2027 the estimate is −$3.60.
When does Rallybio report earnings?
Rallybio is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
Does Rallybio usually beat earnings estimates?
Rallybio reported EPS at or above the analyst estimate in 7 of the last 12 quarters.